| dc.description.abstract | Breast cancer is the frequently diagnosed cancer in the world and the highest
mortality among women. The aim of this study was to evaluate the effect of standard
chemotherapy treatment (dose adjusted for Sri Lankan population) which included
Doxorubicin, Cyclophosphamide and Paclitaxel schedule on liver and renal function
of breast cancer patients. Both prospective and retrospective cross-sectional study
was conducted on seventy-five breast cancer patients who participated in the
oncology clinic at UHKDU. Those who underwent the same standard chemotherapy
treatment with normal baseline liver and renal function tests were recruited for the
study. Mean age and BMI of the study population were 54.04±11.33 years and
26.7±3.89 respectively. Mean values of serum SGOT, SGPT, Creatinine and eGFR
were identified as 27.57 U/L, 31.32 U/L, 0.71 mg/dL and 99.07 ml/min/1.73m2
before the commencement of 16 coursed chemotherapy treatment. Mean values of
SGOT and SGPT showed a statistically significant increase (p<0.05) during the
chemotherapy treatment while mean creatinine and mean eGFR values had no
statistical differences (p>0.05) with the initial laboratory test values. Significant
positive correlations were identified in SGOT (r=0.793) and SGPT (r=0.872) values
however eGFR showed a significant negative correlation (r=-0.757) with the
chemotherapy cycle. Further, serum creatinine levels and chemotherapy cycle
(r=0.579) also showed a positive significant correlation. In conclusion, there was a
statistically significant effect on liver function and no significant effect on renal
function due to the dosed adjusted chemotherapy treatment schedule used on the
study population. The study recommends further studies to assess long term effects
on liver and kidney functions following standard chemotherapy treatment. | en_US |
